-+ 0.00%
-+ 0.00%
-+ 0.00%
Samsung C&T Says Samsung Biologics' PolyPeptide Tender Offer Draws 97.98% Acceptance
Share
Listen to the news
Samsung C&T Says Samsung Biologics' PolyPeptide Tender Offer Draws 97.98% Acceptance
  • Samsung C&T's Nov. 6, 2026, correction disclosed final tender acceptances of 97.98% for Samsung Biologics' PolyPeptide takeover.
  • Acceptances totaled 32,350,302 shares; Samsung Biologics plans to secure 100% ownership through measures including a compulsory purchase under Swiss law.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Samsung C&T Corporation published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261106800926), on November 06, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending